Eli Lilly and Co (LLY) Short Interest Down 26.5% in March

Eli Lilly and Co (NYSE:LLY) saw a large decrease in short interest during the month of March. As of March 29th, there was short interest totalling 10,533,801 shares, a decrease of 26.5% from the March 15th total of 14,330,820 shares. Currently, 1.1% of the shares of the stock are short sold. Based on an average trading volume of 4,479,492 shares, the days-to-cover ratio is currently 2.4 days.

In other Eli Lilly and news, insider Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.09, for a total value of $72,981.00. Following the completion of the sale, the insider now directly owns 4,130 shares of the company’s stock, valued at approximately $334,901.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jeffrey N. Simmons sold 9,625 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.12, for a total transaction of $780,780.00. Following the completion of the sale, the senior vice president now directly owns 152,120 shares of the company’s stock, valued at $12,339,974.40. The disclosure for this sale can be found here. Insiders sold a total of 15,261 shares of company stock valued at $1,225,085 over the last three months. 0.11% of the stock is owned by corporate insiders.

How to Become a New Pot Stock Millionaire

Several institutional investors and hedge funds have recently modified their holdings of LLY. Chevy Chase Trust Holdings Inc. grew its stake in shares of Eli Lilly and by 1.0% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 851,985 shares of the company’s stock valued at $72,879,000 after buying an additional 8,328 shares in the last quarter. Exane Derivatives grew its stake in shares of Eli Lilly and by 2,838.2% in the 4th quarter. Exane Derivatives now owns 18,687 shares of the company’s stock valued at $1,578,000 after buying an additional 18,051 shares in the last quarter. Valeo Financial Advisors LLC bought a new stake in shares of Eli Lilly and in the 3rd quarter valued at approximately $3,463,000. OppenheimerFunds Inc. grew its stake in shares of Eli Lilly and by 8.1% in the 4th quarter. OppenheimerFunds Inc. now owns 43,699 shares of the company’s stock valued at $3,690,000 after buying an additional 3,257 shares in the last quarter. Finally, Lazard Asset Management LLC grew its stake in shares of Eli Lilly and by 0.8% in the 4th quarter. Lazard Asset Management LLC now owns 826,865 shares of the company’s stock valued at $69,835,000 after buying an additional 6,437 shares in the last quarter. Institutional investors own 77.66% of the company’s stock.

Several analysts have issued reports on LLY shares. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $85.52 to $115.00 in a report on Friday, January 5th. Goldman Sachs downgraded Eli Lilly and from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $86.98 to $95.00 in a report on Tuesday, January 16th. Jefferies Group set a $100.00 price objective on Eli Lilly and and gave the stock a “buy” rating in a report on Tuesday, January 16th. Credit Suisse Group downgraded Eli Lilly and from a “neutral” rating to an “underperform” rating and set a $82.00 price objective on the stock. in a report on Monday, January 22nd. Finally, BMO Capital Markets boosted their price objective on Eli Lilly and from $73.00 to $74.00 and gave the stock an “underperform” rating in a report on Thursday, February 1st. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $93.16.

Shares of LLY opened at $80.12 on Tuesday. The stock has a market capitalization of $87,341.06, a PE ratio of 18.72, a price-to-earnings-growth ratio of 1.49 and a beta of 0.26. Eli Lilly and has a fifty-two week low of $73.69 and a fifty-two week high of $89.09. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.01 and a current ratio of 1.32.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. The company had revenue of $6.16 billion for the quarter, compared to the consensus estimate of $5.93 billion. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.95 EPS. sell-side analysts expect that Eli Lilly and will post 4.87 EPS for the current fiscal year.

WARNING: This article was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.chaffeybreeze.com/2018/04/17/eli-lilly-and-co-lly-short-interest-down-26-5-in-march.html.

About Eli Lilly and

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply